Business
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three mont
About this update from Imunon, Inc.
[{"type":"image","alt":"Imunon, Inc.","displaySize":"","headline":null,"caption":"Imunon, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pOVE3xhQvQP6wH..j_xlsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/512f8d6fe64afe67e274ac86630ade62","width":290,"height":91}},"lazy":false},{"type":"text","content":"First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer","length":116,"tagName":"p"},{"type":"text","content":"New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting","length":108,"tagName":"p"},{"type":"text","content":"Company to hold conference call today at 11:00 a.m. ET","length":54,"tagName":"p"},{"type":"text","content":"LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.","length":419,"tagName":"p"},{"type":"text","content":"“IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered groundbreaking data, demonstrating that IMNN-001 is the first immunotherapy to extend both progression-free and overall survival in women newly diagnosed with ovarian cancer when combined with chemotherapy, and we continue to report promising results from the trial further supporting our therapeutic approach, including new translational and safety data this past quarter based on ongoing analyses,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON.","length":669,"tagName":"p"},{"type":"text","content":"“We look forward to building on this data and momentum, with a strong first quarter in 2025. The initiation of the first trial site for our Phase 3 OVATION 3 pivotal study marks a critical step toward our goal o...